EUCTR2017-003356-23-BE进行中（未招募）1 期
A randomized, double-blind, multicenter study to evaluate the efficacy and safety of ALX-0171 versus placebo, in addition to standard of care, in adults who have undergone hematopoietic stem cell transplantation and present with a respiratory syncytial virus respiratory tract infection - Safety and antiviral effect of ALX-0171 in adult HSCT recipients who present with RSV infection
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Ablynx NV
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject is male or female, inpatient/outpatient, agend 18-75 years at screening
- •2. Subject has received an HSCT using any conditioning regiment and for any underlying etiology (an autologous HSCT within 90 days of screening or an allogeneic HSCT within 180 days of screening or an allogeneic HSCT within 365 days of screening with ongoing chronic GVHD requiring systemic immunosuppresive therapy or subjects who have undergone transplantation with T-cell-depleted graft)
- •3. Clinically diagnosed with RSV infection with new onset or acute worsening (in case of pre-existing symptoms due to underlying respiratory disease) of at least one of the following symptoms: rhinorrhea/nasal congestion, sore throat, cough or dyspnea
- •4. Symptoms likely related to RSV infection have appeared within 5 days of screening and their severity requires initial or maintained hospitalization as judged by the investigator
- •5. Documented RSV infection in the upper respiratory tract (ie mid-turbinate nasal swam, nasopharyngeal swab, nasopharyngeal aspirate, nasal wash), as determined by local testing. Samples collected within 5 days of screening will be acceptable. If not yet available the assessments should be performed at the time of screening.
- •6. Subject has: a) diagnosis of RSV LRT disease OR b) diagnosis of RSV URT disease with high risk of progression to LRTI
- •7. Female subjects of childbearing potential (ie fertile, following menarche and until becoming post-menopausal unless permanently sterile) and fertile male subjects must agree to use highly effective contraceptive methods prior to study entry, for the duration of the study participation and for 3 months after the last dose of the study drug.
- •8. Female subjects of childbearing potential (exclusing postmenopausal women, sterilized, ovariectomized and hysterectomized women) must have a negative pregnancy test assessed locally at screening
- •9. Subject is capable to comprehend the informed consent document and provides a signed and dated Informed Consent Form
- •10. Subject must be willing and able (according to the investigator) to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1. Subject has clinically significant bacteremia or fungemia within 7 days of screening for which adequate treatment has not been completed at screening as determined by the investigator
- •2. Subject has clinically significant bacterial, fungal or viral pneumonia (other than the current RSV episode) within 15 days of screening that has not been adequately treated, as determined by the investigator
- •3. Subject is known to be HIV positive
- •4. Subject presents evidence of shock requiring ICU monitoring and/or vasopressor treatment
- •5. Subject requires or is expected to require invasive mechanical ventilation or intensive non-invasive respiratory support (CPAP, BiPAP, HFOT). Standard oxygen supplementation up to 6l/minute is permitted provided it can be interrupted for the duration of the study drug administration
- •6. Subject has been/is being treated with any of the following
- •- any investigational antiviral medication or investigational biological within 5 half lives of screening
- •- any investigational inhaled treatment within 5 half lives of screening
- •- any monoclonal anti-RSV antibodies within 4 months or 5 half lives of screening (whichever is longer)
- •- any investigational vaccine after HSCT
- •- Aerosolized ribavirin within 3 days of screening or needing to initiate or continue this treatment
- •7. Subject is pregnant or breastfeeding
- •8. Subject has history of drug or alcohol abuse within 5 years of screening
- •9. Subject has concurrent life-threatening disease with life expectancy of less than 1 month
- •10. Subject has significant underlying lung disease that confounds the assessment of the RSV episode or any condition that, in the opinion of the investigator, would prevent full participation in this study or would interfere with the evaluation of any study endpoints
- •11. Subject was previously enrolled in a clinical study of ALX-0171 (including the current study ALX0171-C204)
- •12. Subject has a known hypersensitivity to the study drug or any excipient of the study drug
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of ALX-0171 in adults hematopoietic stem cell transplant (HST) recipients who present with an respiratory syncytial virus (RSV) infectioRespiratory Syncytial Virus InfectionEUCTR2017-003356-23-ITABLYNX NV75
进行中（未招募）
1 期
Efficacy and safety of ALX-0171 in adults hematopoietic stem cell transplant (HST) recipients who present with an respiratory syncytial virus (RSV) infectioRespiratory Syncytial Virus InfectionEUCTR2017-003356-23-DEAblynx NV75
进行中（未招募）
1 期
Efficacy and safety of ALX-0171 in adults hematopoietic stem cell transplant (HST) recipients who present with an respiratory syncytial virus (RSV) infectioRespiratory Syncytial Virus InfectionEUCTR2017-003356-23-ESAblynx NV75
进行中（未招募）
1 期
A study to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of skin and nearby tissue infections.EUCTR2017-001605-32-BGBasilea Pharmaceutica International Ltd674
进行中（未招募）
1 期
A study to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of skin and nearby tissue infections.Acute bacterial skin and skin structure infectionsMedDRA version: 20.0 Level: PT Classification code 10052891 Term: Skin bacterial infection System Organ Class: 10021881 - Infections and infestationsEUCTR2017-001605-32-HUBasilea Pharmaceutica International Ltd674